evidence card · vitamin_k2_bone_mineral_density

Vitamin K2 supplementation improves bone mineral density and reduces fracture risk

Moderate evidence, mixed interpretation

H3 ≈ mixed stakes moderate

1 post scored · across 1 account · 5 sources

Summary

Vitamin K2 (menaquinones, especially MK-4 and MK-7) activates osteocalcin via gamma-carboxylation, which is biologically plausible for bone metabolism. RCTs and meta-analyses in postmenopausal women show modest improvements in lumbar BMD and reductions in undercarboxylated osteocalcin, with some Japanese trials (using pharmacologic MK-4 at 45 mg/day) reporting fracture reductions. However, results are heterogeneous: larger Western trials (e.g., Knapen, Binkley) show smaller or null BMD effects, and the strongest fracture evidence comes from a geographically restricted body of Japanese trials with risk-of-bias concerns. Major osteoporosis guidelines (AACE/ACE, NOF, IOF) do not endorse vitamin K2 as a first-line therapy. Evidence for CVD risk reduction is weaker still and not addressed by this card.

Five-score assessment

Consensus 2/5

Major osteoporosis guidelines (Endocrine Society, AACE, NOF, IOF) do not recommend vitamin K2 as osteoporosis therapy; only Japan's regulatory framework endorses pharmacologic MK-4.

Evidence certainty 2/5

GRADE-like quality is moderate-to-low: heterogeneity between Japanese MK-4 trials and Western MK-7 trials, risk-of-bias concerns in the fracture-benefit literature, and wide confidence intervals on BMD effects.

Replication 3/5

Cockayne 2006 meta-analysis and Knapen 2013 MK-7 RCT show directionally consistent BMD/fracture benefits; multiple smaller trials reproduce reductions in undercarboxylated osteocalcin.

Contradiction 3/5

Binkley 2009 RCT and Mott 2019 updated meta-analysis found no meaningful BMD effect; fracture benefit appears largely confined to a Japanese MK-4 literature with methodological concerns.

Directness 3/5

Mix of surrogate (BMD, ucOC) and patient-important (fracture) outcomes, with the strongest fracture evidence restricted to a single geographic region.

Scope

Population

Adults, primarily postmenopausal women with or at risk of osteoporosis

Intervention

Vitamin K2 (MK-4 or MK-7) oral supplementation, typically 90-45,000 mcg/day

Outcome

Bone mineral density (lumbar/femoral), undercarboxylated osteocalcin, fracture incidence

Not supported for

CVD event reduction
Coronary artery calcium regression in general adult populations
Children or healthy young adults without bone disease
Replacement for established osteoporosis therapy (bisphosphonates, denosumab)

Evidence sources

Supporting (2)

meta Cockayne et al. 2006, Arch Intern Med — Vitamin K and bone loss/fractures meta-analysis ↗

Meta-analysis of 13 RCTs found vitamin K supplementation (predominantly MK-4) associated with reduced fracture risk in postmenopausal women, though dominated by Japanese trials.
rct Knapen et al. 2013, Osteoporos Int — Three-year low-dose MK-7 RCT ↗

3-year RCT of 180 mcg/day MK-7 in postmenopausal women showed small but statistically significant preservation of lumbar and femoral neck BMD vs placebo.

Contradicting (2)

rct Binkley et al. 2009, J Bone Miner Res — MK-4 in postmenopausal women ↗

12-month RCT of MK-4 45 mg/day in North American postmenopausal women found no effect on BMD at spine or hip despite reduction in undercarboxylated osteocalcin.
meta Mott et al. 2019, Osteoporos Int — Effect of vitamin K on bone mineral density and fractures ↗

Updated meta-analysis found no significant effect of vitamin K supplementation on BMD at most sites and questioned the fracture benefit once Japanese MK-4 trials were examined for risk of bias.

Neutral / context (1)

guideline Endocrine Society 2019/2020 Postmenopausal Osteoporosis Guideline ↗

Does not recommend vitamin K2 as pharmacologic therapy for osteoporosis; endorses bisphosphonates, denosumab, and anabolics as first-line.

Account mentions

@BradStanfieldMD stance: supports · alignment: ambiguous · score 98/100 · 2025-11-16 post ↗